Climb Bio, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information
Director and Officer Trading Arrangements
The adoption or termination of contracts, instructions or written plans for the purchase or sale of our securities by our Section 16 officers and directors for the three months ended September 30, 2026, which are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act (“Rule 10b5-1 Plan”), was as follows:
| Name (Title) | Action taken(Date of Action) | Type of Trading Arrangement | Nature of TradingArrangement | Duration of TradingArrangement | Maximum Number of Securities to be Purchased or Sold Pursuant to the Rule 10b5-1 Trading Plan |
|---|---|---|---|---|---|
| Stephen Thomas (Director) | Adoption (September 22, 2026) | Rule 10b5-1 trading arrangement | Sale | Until January 4, 2028, or, if earlier, upon the completed sale of the maximum shares | 150,000 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.